SCS Pharmaceuticals

scPharmaceuticals is a commercial-stage pharmaceutical company specializing in the development and commercialization of products designed to optimize the delivery of infused therapies, particularly for cardiorenal care. The company's flagship product, FUROSCIX, is an FDA-approved on-body infusor that delivers a proprietary formulation of furosemide subcutaneously, providing IV-equivalent diuresis in an outpatient setting for patients with chronic heart failure and chronic kidney disease. This innovative approach aims to reduce the burden of hospitalizations and lower overall healthcare costs by shifting care to the home. In October 2025, scPharmaceuticals was acquired by MannKind Corporation, integrating its cardiorenal expertise into MannKind's broader cardiometabolic and orphan lung portfolio.